Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 4
2008 4
2009 8
2010 14
2011 19
2012 28
2013 23
2014 24
2015 20
2016 14
2017 15
2018 14
2019 6
2020 14
2021 12
2022 10
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Asenapine.
Weber J, McCormack PL. Weber J, et al. CNS Drugs. 2009 Sep;23(9):781-92. doi: 10.2165/11200860-000000000-00000. CNS Drugs. 2009. PMID: 19689168 Review.
It is being developed for the treatment of schizophrenia and bipolar mania. In two randomized, controlled trials of asenapine monotherapy and in one randomized, controlled trial of adjunctive asenapine therapy in adult patients with bipolar I disorder, sublingual …
It is being developed for the treatment of schizophrenia and bipolar mania. In two randomized, controlled trials of asenapine monothe …
New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. Pahwa M, et al. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. Curr Psychiatry Rep. 2021. PMID: 34843030 Review.
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapi
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, …
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. Rosenblat JD, et al. Can J Psychiatry. 2023 Jan;68(1):5-21. doi: 10.1177/07067437221111371. Epub 2022 Aug 17. Can J Psychiatry. 2023. PMID: 35975555 Free PMC article. Review.
RESULTS: Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). ...Small sample sizes an …
RESULTS: Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed …
Asenapine.
Meltzer HY, Dritselis A, Yasothan U, Kirkpatrick P. Meltzer HY, et al. Nat Rev Drug Discov. 2009 Nov;8(11):843-4. doi: 10.1038/nrd3027. Nat Rev Drug Discov. 2009. PMID: 19876039
In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults....
In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or …
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Mauri MC, et al. Clin Pharmacokinet. 2018 Dec;57(12):1493-1528. doi: 10.1007/s40262-018-0664-3. Clin Pharmacokinet. 2018. PMID: 29915922 Review.
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. ...This review concentrates on the clinical pharmacokinetic data related to cl …
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining lo …
Asenapine: A Review in Schizophrenia.
Plosker GL, Deeks ED. Plosker GL, et al. CNS Drugs. 2016 Jul;30(7):655-66. doi: 10.1007/s40263-016-0363-2. CNS Drugs. 2016. PMID: 27356921 Review.
The most frequently reported adverse events with asenapine are somnolence, akathisia and oral hypoesthesia. Although potentially associated with more extrapyramidal symptoms, asenapine appears to have less weight gain and metabolic effects than some ot …
The most frequently reported adverse events with asenapine are somnolence, akathisia and oral hypoesthesia. Although potential …
Asenapine for the Treatment of Psychotic Disorders.
Orr C, Deshpande S, Sawh S, Jones PM, Vasudev K. Orr C, et al. Can J Psychiatry. 2017 Feb;62(2):123-137. doi: 10.1177/0706743716661324. Epub 2016 Aug 6. Can J Psychiatry. 2017. PMID: 27481921 Free PMC article. Review.
Primary outcome measures were changes in the Positive and Negative Syndrome Scale (PANSS) total score and the incidence of withdrawal due to adverse effects. RESULTS: Eight randomized clinical trials, encompassing 3765 patients, that compared asenapine with p …
Primary outcome measures were changes in the Positive and Negative Syndrome Scale (PANSS) total score and the incidence of withdrawal due to …
Asenapine versus placebo for schizophrenia.
Hay A, Byers A, Sereno M, Basra MK, Dutta S. Hay A, et al. Cochrane Database Syst Rev. 2015 Nov 24;2015(11):CD011458. doi: 10.1002/14651858.CD011458.pub2. Cochrane Database Syst Rev. 2015. PMID: 26599405 Free PMC article. Review.
Individuals receiving asenapine demonstrated significantly fewer incidents of serious adverse effects (1 RCT, n = 386, RR 0.29, 95% CI 0.14 to 0.63, very low-quality evidence) at medium-term. ...AUTHORS' CONCLUSIONS: There is some, albeit preliminary, evidenc …
Individuals receiving asenapine demonstrated significantly fewer incidents of serious adverse effects (1 RCT, n = 386, …
Asenapine, Aggression, and Affinity.
El-Mallakh RS. El-Mallakh RS. J Clin Psychiatry. 2022 Sep 28;83(5):22lr14564. doi: 10.4088/JCP.22lr14564. J Clin Psychiatry. 2022. PMID: 36170205 Free article.
Asenapine for the treatment of bipolar disorder.
Marazziti D, Mucci F, Falaschi V, Dell'Osso L. Marazziti D, et al. Expert Opin Pharmacother. 2019 Aug;20(11):1321-1330. doi: 10.1080/14656566.2019.1617849. Epub 2019 May 27. Expert Opin Pharmacother. 2019. PMID: 31132287 Review.
Its tolerability profile is good, and its most common side effects are somnolence, light extrapyramidal symptoms, dizziness, weight gain, and oral (but reversible) hypoesthesia. Taken together, the published studies indicate that asenapine might be an effective ther …
Its tolerability profile is good, and its most common side effects are somnolence, light extrapyramidal symptoms, dizziness, weight g …
220 results